Silymarin: a review of its clinical properties in the management of hepatic disorders.
about
Novel Investigations of Flavonoids as Chemopreventive Agents for Hepatocellular CarcinomaDrug-Induced Liver Toxicity and Prevention by Herbal Antioxidants: An OverviewSilymarin in Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis of Randomized Controlled TrialsTreatment of amatoxin poisoning: 20-year retrospective analysis[Effect of silymarin on liver health and quality of life. Results of a non-interventional study].Herbal modulation of P-glycoprotein.Silymarin in non alcoholic fatty liver disease.Enhanced inhibition of lung adenocarcinoma by combinatorial treatment with indole-3-carbinol and silibinin in A/J mice.Cosmeceuticals and silibininHerbal medicine and hepatocellular carcinoma: applications and challengesSilibinin enhances ultraviolet B-induced apoptosis in mcf-7 human breast cancer cellsEffect of ribavirin alone or combined with silymarin on carbon tetrachloride induced hepatic damage in rats.The effect of silibinin in enhancing toxicity of temozolomide and etoposide in p53 and PTEN-mutated resistant glioma cell linesFlavonoids: A versatile source of anticancer drugs.The ameliorative effect of silibinin against radiation-induced lung injury: protection of normal tissue without decreasing therapeutic efficacy in lung cancer.Pyranone natural products as inspirations for catalytic reaction discovery and developmentSilymarin Accelerates Liver Regeneration after Partial HepatectomyEffects of silymarin on neuropathic pain and formalin-induced nociception in mice.Complementary and alternative medicines in prostate cancer: from bench to bedside?Silibinin induces mitochondrial NOX4-mediated endoplasmic reticulum stress response and its subsequent apoptosisConsumer satisfaction and efficacy of the hangover cure after-effect(©).Chemoenzymatic Synthesis, Characterization, and Scale-Up of Milk Thistle Flavonolignan Glucuronides.Antioxidant and Anti-Hepatitis C Viral Activities of Commercial Milk Thistle Food SupplementsFree Radical Scavenging and Antioxidant Activities of Silymarin Components.Silymarin and epithelial cancer chemoprevention: how close we are to bedside?Direct targeting of MEK1/2 and RSK2 by silybin induces cell-cycle arrest and inhibits melanoma cell growth.Chemopreventive efficacy of silymarin in skin and prostate cancer.A silybin-phospholipids complex counteracts rat fatty liver degeneration and mitochondrial oxidative changes.Combinatorial strategies for cancer eradication by silibinin and cytotoxic agents: efficacy and mechanisms.Free radical scavenging activity of silibinin in nitrite-induced hemoglobin oxidation and membrane fragility models.Real time in vivo investigation of superoxide dynamics in zebrafish liver using a single-fiber fluorescent probe.Kava, a tonic for relieving the irrational development of natural preventive agents.Survival predictors in patients treated with a molecular adsorbent recirculating systemSilibinin and Paclitaxel Cotreatment Significantly Suppress the Activity and Lung Metastasis of Triple Negative 4T1 Mammary Tumor Cell in Mice.Silibinin inhibits accumulation of myeloid-derived suppressor cells and tumor growth of murine breast cancerPharmacokinetic changes of drugs in a rat model of liver cirrhosis induced by dimethylnitrosamine, alone and in combination with diabetes mellitus induced by streptozotocin.Silibinin causes apoptosis and cell cycle arrest in some human pancreatic cancer cells.Partially PEGylated PAMAM dendrimers as solubility enhancers of Silybin.Search for Antiprotozoal Activity in Herbal Medicinal Preparations; New Natural Leads against Neglected Tropical Diseases.The Protective Role of Phenolic Compounds Against Doxorubicin-induced Cardiotoxicity: A Comprehensive Review.
P2860
Q26767372-4DAABE59-48B4-48EE-826F-068C51559897Q26767516-141B4D59-DC4D-4F46-929C-6BD5A005C67DQ28071012-7E0BF8B8-6E8A-4537-A13E-BE2D1984CE42Q28217079-E7EA9124-7373-4DE3-A728-42B8946F42B3Q33465520-3BEAD1EE-517E-4AA4-8A44-982A4AB3F83BQ34312035-FD7E47DE-F774-4B0A-933A-DB8CC4ADF0C3Q34650071-83A6DBC4-044D-4352-8369-4CA6D2DEF0BBQ34734130-339D0A6C-487A-409A-9CA1-4AFFC4067B8CQ34998525-7AD62677-290E-4DA8-96A6-CB9B9BFD5D48Q35117008-102649E2-D5C2-43F3-A50A-B96FB9FA0F58Q35142107-E27F611D-A8E3-438E-977B-0DD77E0D8497Q35161778-2DCDCDC5-4146-4D5A-8B73-39176EEE29EEQ35166452-C81343A5-F877-445E-840C-961F782AB13AQ35533265-4BD7CCE8-A96E-4A1C-8C7E-699A29452A45Q35682826-E829C41C-E046-49B8-BD9C-8662677DA72FQ35878745-DC6112DB-5458-4A56-BCCD-4B806147E610Q35962716-37A3E23A-FA88-480E-9C43-6B03EB0E5646Q36017190-4915888E-C728-4656-9CE3-3009D2EC2B90Q36051522-F7BD6E4E-166D-4588-B2C7-DA72ACAC722EQ36074243-117C7B2E-78DC-4FD2-9E93-55813A052A43Q36125008-214CAD04-EC0D-46A5-8872-0BF81E97F9ABQ36186132-76918A82-BC7A-4099-97D4-03F5EB196948Q36334863-9E7A7B35-AEA8-499C-A5A5-AB7E2924C81BQ36335116-572B20CB-E827-4054-A713-44D739C6188BQ36690472-E6966FB4-27C1-4C79-A288-F3DB998C99F2Q36816318-41111BAA-AC4D-44FF-B841-D3ACE2A53D0AQ36840442-374A9B77-D226-4D7A-96A5-5E75FCE84E5AQ36871971-FA330936-B5AD-49A4-A842-4632CFA2520BQ36920794-22B40257-4385-4D24-AF6E-208A64511329Q37099072-D99C87B8-047A-4E21-929F-F41EFDDCB78FQ37167719-707F31BA-9579-4F15-AC56-212BEC067451Q37175348-6DB460F7-2CFA-44F4-AB2A-563B1F49898FQ37241955-98A4F2BC-21BE-467D-AFB3-6EB117E2110DQ37618125-8531CE4A-E919-47F7-AACC-4D3E7E925511Q37703362-708D723F-FED2-4BA5-84B5-C5046C17705BQ38214801-A78EF6B6-5EEE-4620-91F3-B40576CFDC8EQ38551068-C454499B-64CB-4DAF-BB6B-E2EC00CD6417Q38736230-87C34587-FE50-4CCC-9760-8158C1E747BBQ38845902-715ACA26-517F-4ED4-9137-6F1887B16B68Q38875916-BA3B5E93-5C57-4FFF-A524-4E881955AF12
P2860
Silymarin: a review of its clinical properties in the management of hepatic disorders.
description
2001 nî lūn-bûn
@nan
2001 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Silymarin: a review of its clinical properties in the management of hepatic disorders.
@ast
Silymarin: a review of its clinical properties in the management of hepatic disorders.
@en
Silymarin: a review of its clinical properties in the management of hepatic disorders.
@nl
type
label
Silymarin: a review of its clinical properties in the management of hepatic disorders.
@ast
Silymarin: a review of its clinical properties in the management of hepatic disorders.
@en
Silymarin: a review of its clinical properties in the management of hepatic disorders.
@nl
prefLabel
Silymarin: a review of its clinical properties in the management of hepatic disorders.
@ast
Silymarin: a review of its clinical properties in the management of hepatic disorders.
@en
Silymarin: a review of its clinical properties in the management of hepatic disorders.
@nl
P1433
P1476
Silymarin: a review of its clinical properties in the management of hepatic disorders.
@en
P2093
K Wellington
P304
P356
10.2165/00063030-200115070-00005
P577
2001-01-01T00:00:00Z
P6179
1005403788